Skip to main content

Advertisement

SpringerLink
Log in

Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV

  • Published:
Infection Aims and scope Submit manuscript

Summary

Several first-generation nucleoside analogues have been tested against chronic hepatitis B virus (HBV) infection, but trials were unsuccessful or accompanied by toxicity. Recently, oral second-generation nucleoside analogues have been developed that have potent activity against HBV. The best-studied compound so far is lamivudine ((-)2′-deoxy-3′-thiacytidine; 3TC). Lamivudine is an inhibitor of reverse transcriptase (RT) activity and is in clinical use in human immunodeficiency virus (HIV)-infected individuals. As several studies on the use of lamivudine for hepatitis B show, the development of resistance in the viral polymerase under lamivudine treatment, however, causes a significant clinical problem. All other drugs in advanced clinical development for HBV are nucleosides; cross-resistance is therefore expected in most cases. The history of HIV treatment demonstrates that new classes of drugs, the protease inhibitors and non-nucleosidic inhibitors of RT, allowed for a longer-term clinical benefit when used in combination with nucleoside analogues. The development of non-nucleosidic compounds with different modes of action therefore appears very important for the treatment of chronic hepatitis B as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jaeckel, E., Manns, M. P.: Experience with lamivudine against hepatitis B virus. Intervirology 40 (1997) 322–336.

    PubMed  CAS  Google Scholar 

  2. Hepatitis overview. Clinica. Doc. No.: C00529354 (1997).

  3. Market dynamics: global opportunities in hepatitis to 2010. Datamonitor Americas. New York (1998).

  4. Coleman, P. J., McQuillan, G. M., Moyer, L. A., Lambert, S. B., Margolis, H. S.: Incidence of hepatitis B virus infection in the United States, 1976–1994: estimates from the National Health and Nutrition Examination Surveys. J. Infect. Dis. 178 (1998) 954–959.

    PubMed  CAS  Google Scholar 

  5. Yao, G. B.: Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 38 (Suppl. 2) (1996) S39-S42.

    PubMed  Google Scholar 

  6. Kane, M. A.: The global epidemiology of hepatitis B: Soz. Präventivmed. 43 (Suppl. 1), (1998) S24-S26.

    Article  Google Scholar 

  7. de Jongh, F. E., Janssen, H. L., de Man, R. A., Hop, W. C., Schalm, S. W., van Blankenstein, M.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver (see comments). Gastroenterology 103 (1992) 1630–1635.

    PubMed  Google Scholar 

  8. Decker, R. H.: Diagnosis. In:Zuckerman, A. J., Thomas, H. C. (eds.): Viral hepatitis. Churchill Livingstone. Edinburgh 1993, pp. 165–184.

    Google Scholar 

  9. Rehermann, B., Manns, M. P.: Immunologic aspects of acute and chronic hepatitis B and C. Curr. Opin. Gastroenterol. 12 (1996) 554–559.

    Article  Google Scholar 

  10. Rehermann, B., Ferrari, C., Pasquinelli, C., Chisari, F.V.: The hepatitis-B virus persists for decades after patients recover from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 2 (1996) 1104–1108.

    Article  PubMed  CAS  Google Scholar 

  11. Koziel, M. J.: The immunopathogenesis of HBV infection. Antiviral Ther. 3 (Suppl. 3) (1998) 13–24.

    CAS  Google Scholar 

  12. Pharmaprojects, Doc. No.: PH029050 (1999).

  13. Trippler, M., zum Buschenfelde, K. H. M., Gerken, G.: HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. J. Virol. Methods 78 (1999) 129–147.

    Article  PubMed  CAS  Google Scholar 

  14. Chisari, F. V., Ferrari, C.: Hepatitis-B virus immunopathogenesis. Annual Review of Immunology 13 (1995) 29–60.

    Article  PubMed  CAS  Google Scholar 

  15. Trepo, C., Zoulim, F., Alonso, C., Petit M. A., Pichoud, C., Vivitski, L.: Diagnostic markers of viral hepatitis-B and hepatitis-C. Gut 34 (1993) S20-S25.

    PubMed  CAS  Google Scholar 

  16. Muller, R., Samuel, D., Fassati, L. R., Benhamou, J. P., Bismuth, H., Alexander, G. J. M.: Eurohep consensus report on the management of liver transplantation for hepatitis-B virus infection. J. Hepatol. 21 (1994) 1140–1143.

    Article  PubMed  CAS  Google Scholar 

  17. Marques, A. R., Straus, S. E.: Advances in the treatment of chronic hepatitis B virus infection. Reviews in Medical Virology 8 (1998) 223–234.

    Article  PubMed  CAS  Google Scholar 

  18. Poordad, F. F., Gish, R. G.: Evolving therapies for the treatment of viral hepatitis. Emerging Drugs 4 (1999) 15–35.

    Article  CAS  Google Scholar 

  19. Hoofnagle, J. H.: Therapy of viral hepatitis. Digestion 59 (1998) 563–578.

    Article  PubMed  CAS  Google Scholar 

  20. Prieto, M., Cordoba, J., Rayon, J. M., Garcia-Herola, A., Berenguer, M., Carraseo D., Olaso, V., Mir, J., Berenguer, J.: Good response to lamivudine therapy in patients with de novo hepatitis B following orthotopic liver transplantation: a pilot study. Hepatology 28 (Suppl.) (1998) 348A.

    Google Scholar 

  21. Perillo, R. P.: Treatment of chronic hepatitis B with IFN: experience in western countries. Semin. Liver Dis. 9 (1989) 240–241.

    Google Scholar 

  22. Hoofnagle, J. H., Hanson, R. G., Minuk, G. Y., Pappas S. C., Schafer, D. F., Dusheiko, G. M., Straus, S. E., Popper, H., Jones, E. A.: Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 86 (1984) 150–157.

    PubMed  CAS  Google Scholar 

  23. Minul, G. Y., German, G. B., Bernstein, C., Benarroch, A., Gauthier, T., Sekla, L.: A piliot study of steroid withrawal followed by oral acyclovir in the treatment of chronic type-B hepatitis. Clin. Invest. Med.-Medicine Clinique et Experimentale 15 (1992) 506–512.

    Google Scholar 

  24. Macilwain, C.: NIH, FDA seek lessons from hepatitis-B drug trial death. Nature 364 (1993) 275.

    PubMed  CAS  Google Scholar 

  25. Marwick, C.: NIH panel report of ‘no flaws’ in FIAU trial at variance with FDA report, new probe planned (news). JAMA 272 (1994) 9–11.

    Article  PubMed  CAS  Google Scholar 

  26. Fried, M. W., Fong, T. L., Swain, M. G., Park, Y., Beams, M. P., Banks, S. M., Hoofnagle, J. H., Dibisceglie, A. M.: Therapy of chronic hepatitis-B with a 6-month course of ribavirin. J. Hepatol. 21 (1994) 145–150.

    Article  PubMed  CAS  Google Scholar 

  27. Gish, R. G., Lau, J. Y. N., Brooks, L., Fang, J. W. S., Steady, S. L., Imperial, J. C., Garciakennedy, R., Esquivel, C. O., Keeffe, E. B.: Ganciclovir treatment of hepatitis-B virus infection in liver-transplant recipients. Hepatology 23 (1996) 1–7.

    Article  PubMed  CAS  Google Scholar 

  28. Anand, B. S., Yoffe, B., Young, J. B.: Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patients. J. Clin. Gastroenterol. 22 (1996) 144–146.

    Article  PubMed  CAS  Google Scholar 

  29. Nelson, H.: FDA advised to license three anti-HIV agents (news). Lancet 346 (1995) 1358.

    Article  PubMed  CAS  Google Scholar 

  30. Balzarini, J.: Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharmacy World and Science 16 (1994) 113–126.

    Article  PubMed  CAS  Google Scholar 

  31. Hong, J. H., Choi, Y., Chun, B. K., Lee, K., Chu, C. K.: Current status of anti-HBV chemotherapy. Archives of Pharmacal Research 21 (1998) 89–105.

    Article  PubMed  CAS  Google Scholar 

  32. Severini, A., Liu, X. Y., Wilson, J. S., Tyrrell, D. L.: Mechanism of inhibition of duck hepatitis B virus polymerase by(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39 (1995) 1430–1435.

    PubMed  CAS  Google Scholar 

  33. Cui, L., Schinazi, R. F., Gosselin, G., Imbach, J. L., Chu, C. K., Rando, R. F., Revankar, G. R., Sommadossi, J. P.: Effect of betaenantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatoxicity. Biochem. Pharmacol. 52 (1996) 1577–1584.

    Article  PubMed  CAS  Google Scholar 

  34. Parker, W. B., Cheng, Y. C.: Mitochondrial toxicity of antiviral nucleoside analogues. J. NIH Res. 6 (1994) 57–61.

    Google Scholar 

  35. Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T. S., Liu S.H., Trepo, C. Cheng, Y. C.: 2′,3′-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus resverse transcription and suppress viral DNA synthesis in hepatocytes, bothin vitro andin vivo. Antimicrob. Agens Chemother 40 (1996) 448–453.

    CAS  Google Scholar 

  36. Lai, C. L., Chien, R. N., Leung, N. W. Y., Chang, T. T., Guan, R., Tai, D.I., Ng K. Y., Wu, P. C., Dent, J. C., Barber, J., Stephenson, S. L., Gray, D. F.: A one-year trial of lamividine for chronic hepatitis B. N. Engl. J. Med. 339 (1998) 61–68.

    Article  PubMed  CAS  Google Scholar 

  37. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., Rubin, M.: A prelinary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333 (1995) 1657–1661.

    Article  PubMed  CAS  Google Scholar 

  38. Scrip, Doc. No.: S00622582 (1999).

  39. Dienstag, J., Schiff, E. R., Wright, T., Perrillo, R., Hann, H. W., Crowther, L., Woessner, M., Rubin, M., Brown, N., Group US Lamividine Investigator: Lamivudine treatment for one year in previously untreated US hepatitis B patients: histologic improvement and hepatitis B e antigen seroconversion. Gastroenterology 114 (1998) pA1235.

    Article  Google Scholar 

  40. Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., Thomas, H. C.: A double blind, placebo controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Virol. Hepatitis 3 (1996) 211–215.

    CAS  Google Scholar 

  41. Scrip, Doc. No.: S00620466, (1999).

  42. Scrip, Doc. No.: S00611502, (1999).

  43. Gilson, R. J. C., Murray-Lyon, I. M., Nelson, M. R., Rice, S. J., Tedder, R. S., Murray, A., Jaffe, H. S., Weller, I. V. D.: Extended treatment with adefovir dipivoxil in patients with chronic hepatitis B virus infection. Hepatology 28 (1998) 1316.

    Google Scholar 

  44. Xiong, X., Flores, C., Yang, H., Westland, C. E., Tolle, J. J., Gibbs, C. S.: Mutations in human hepatitis B virus polymerase associated with resistance to lamivudine and famiciclovir do not decrease sensitivity to adefovir. Antiviral Res. 37 (1998) pA66.

    Google Scholar 

  45. Gibbs, C., Flores, C., Yang, H., Westland, C., Toole, J., Xiong, X.: HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir. J. Hepatol. 28 (Suppl. 1) (1998) 111.

    Article  Google Scholar 

  46. Xiong, X. F., Flores, C., Yang, H., Toole, J. J., Gibbs, C. S.: Mutations in hepatitis B DNA polymerase associated resistance to lamivudine do not confer resistance to adefovirin vitro. Hepatology 28 (1998) 1669–1673.

    Article  PubMed  CAS  Google Scholar 

  47. Fu, L., Liu, S. H., Cheng, Y. C.: Sensitivity of L-(-)2′,3′-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem. Pharmacol. 57 (1999) 1351–1359.

    Article  PubMed  CAS  Google Scholar 

  48. Bain, V. G., Kneteman, N. M., Ma, M. M., Gutfreund, K., Shapiro, J. A. Fischer, K., Tipples, G., Lee, H., Jewell, L. D., Tyrrell, D. L.: Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 62 (1996) 1456–1462.

    Article  PubMed  CAS  Google Scholar 

  49. Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Knetemann, N. M., Tyrrell, D. L. J.: Mutation in HBV RNA-dependent DNA-polymerase confers resistance to lamivudinein vivo. Hepatology 24 (1996) 714–717.

    PubMed  CAS  Google Scholar 

  50. Ling, R., Mutimer, D., Ahmed, N., Boxall E. H., Elias, E., Dusheiko, G. M., Harrison, T. J.: Selection of mutations in the hepatitis-B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711–713.

    Article  PubMed  CAS  Google Scholar 

  51. Chayama, K., Suzuki, Y., Kobayashi, M., Kobayashi, M., Tsubota, A., Hashimoto, M., Miyano, Y., Koike, H., Kobayashi, M., Koida, I., Arase, Y., Saitoh, S., Murashima, N., Ikeda, K., Kumada, H.: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 (1998) 1711–1716.

    Article  PubMed  CAS  Google Scholar 

  52. Niesters, H. G. M., Honkoop, P., Haagsma, E. B., deMan, R. A., Schalm, S. W., Osterhaus, A. D. M. E.: Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J. Infect. Dis. 177 (1998) 1382–1385.

    Article  PubMed  CAS  Google Scholar 

  53. Cane, P.A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E., Pillay, D.: Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antiviral Ther. 4 (1999) 7–14.

    CAS  Google Scholar 

  54. Allen, M. I., Deslauriers, M., Andrews, C. W., Tipples, G. A., Walters, K. A., Tyrrell, D. L. J., Brown, N., Condreay, L. D.: Identification and characterization of mutations in hepatitis B virus resitant to lamivudine. Hepatology 27 (1998) 1670–1677.

    Article  PubMed  CAS  Google Scholar 

  55. Yoshida, E. M., Ma, M. M., Davis, J. E. Fischer, K. P., Kneteman, N. M., Erb, S. R., Tyrrell, D. L., Bain, V. G.: Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long term follow-up. Can. J. Gastroenterol. 12 (1998) 125–129.

    PubMed  CAS  Google Scholar 

  56. De Man, R. A., Bartholomeusz, A., Locarnini, S., Niesters, H. G. M., Zondervan, P. E.: The occurrence of sequential viral mutations in a liver transplant recipient reinfected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J. Hepatol. 26 (Suppl. 1) (1997) 77.

    Google Scholar 

  57. deMan, R. A., Bartholomeusz, A. I., Niesters, H. G. M., Zondervan, P. E., Locarnini, S. A.: The sequential occurence of viral mutations in liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29 (1998) 669–675.

    Article  CAS  Google Scholar 

  58. Bartholomeusz, A., Locarnini S.: Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine. International Antiviral News 5 (1997) 123–124.

    Google Scholar 

  59. Whalley, S., Manolakopoulos, S., Brown, D., Davies, S., Ling, R., Harrison, T., Dusheiko, G.: Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pretreatment viral load in patients with chronic infection. Gut 42 (Suppl. 1) (1998) 14.

    Google Scholar 

  60. Mutimer, D., Pillay, D., Dragon, E., Tang, H., Ahmed, M., O'Donnell, K., Shaw, J., Burroughs, R., Rand, D., Cane, P., Martin, B., Buchan, S., Boxall, E., Barnat, S., Gutekunst, K., McMaster, P., Elias, E.: High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 30 (1999) 715–721.

    Article  PubMed  CAS  Google Scholar 

  61. Ling, R., Harrison, T. J.: Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J. Gen. Virol. 80 (Part 3) (1999) 601–606.

    PubMed  CAS  Google Scholar 

  62. Ono-Nita, S. K., Kato, N., Shiratori, Y., Masaki, T., Lan, K. H., Carrilho, F. J., Omata, M.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study byin vitro full-length viral DNA transfection. Hepatology 29 (1999) 939–945.

    Article  PubMed  CAS  Google Scholar 

  63. Fu, L., Cheng, Y. C.: Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(−)SddC (3TC) resistance. Biochem. Pharmacol. 55 (1998) 1567–1572.

    Article  PubMed  CAS  Google Scholar 

  64. Ladner, S. K., Miller, T. J., King, R. W.: The M539V polymerase variant in human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob. Agents Chemother. 42 (1998) 2128–2131.

    PubMed  CAS  Google Scholar 

  65. Ladner, S. K., Miller, T. J., Otto, M. J., King, R. W.: The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemistry & Chemotherapy 9 (1998) 65–72.

    CAS  Google Scholar 

  66. Heathcote, J., Schalm, S. W., Cianciara, J., Farrell, G., Feinmann, V., Shermann, M., Dhillon, A. P., Moorat, A. E., Gray, D. F.: Lamivudine and intron: a combination treatment in patients with chronic hepatitis B infection. J. Hepatol. 28 (Suppl. 1) (1998) 43.

    Article  Google Scholar 

  67. Kim, J. W., Lee, M. Y., Chin, Y. J., Lim, C. Y., Song, I. H.: Interferon alpha versus interferon alpha and lamivudine in the treatment of chronic active hepatitis B. 8th International Symposium on Viral Hepatitis 121, 22 January 1998.

  68. Schiff, E., Karayalcin, S., Grimm, I., Perrillo, R., Dienstag, J., Husa, P., Schalm, S., Crowther, L., Sullivan, M., Woessner, M., McPhillips, P., Brown, N., Group International Lamivudine Investigator: A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28 (Suppl.) (1998) p388A.

    Google Scholar 

  69. Mutimer, D., Naoumov, N., Honkoop, P., Marinos, G., Ahmed, M., deMan, R., McPhillips, P., Johnson, M., Williams, R., Elias, E., Schalm, S.: Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepatol. 28 (1998) 923–929.

    Article  PubMed  CAS  Google Scholar 

  70. Rübsamen-Waigmann, H.: Antiviral therapies: progress, resistance and trends. Nova Acta Leopoldina NF 78 (1999) 295–312.

    Google Scholar 

  71. Benson, E. M., Clarkson, J., Law, M., Marshall, P., Kelleher, A. D., Smith, D. E., Patou, G., Stewart, G. J., Cooper, D. A., Ffrench, R. A.: Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals. AIDS Res. Hum. Retroviruses 15 (1999) 105–113.

    Article  PubMed  CAS  Google Scholar 

  72. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., Lafond, R., Yuan, L. L., Chisari, F. V., Furze, J., Bartholomeuz, R., Chesnut, R. W.: Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T-lymphocyte response in humans. J. Clin. Invest. 95 (1995) 341–349.

    Article  PubMed  CAS  Google Scholar 

  73. Pharmaprojects, Doc. No.: PH017693 (1999).

  74. Alexopoulou, A., Zafiropoulou, R., Papakonstantinou, A., Hadziyannis, S. J.: Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with interferon. Evaluation of long-term efficacy. Hepatology 28 (Suppl.) (1998) 490.

    Google Scholar 

  75. Terrault, N. A., Wright, T. L., Roberts, J. P., Ascher, N. L.: Combined short-term hepatitis B immunoglobulin (HBIG) and long-term lamivudine versus HBIG monotherapy as hepatitis B virus prophylaxis in liver transplant recipients. Hepatology 28 (Suppl.) (1998) 389.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Virology, Geschäftsbereich Pharma, Bayer AG, D-42096, Wuppertal, Germany

    K. Deres &  H. Rübsamen-Waigmann

Authors
  1. K. Deres
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Rübsamen-Waigmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deres, K., Rübsamen-Waigmann, H. Development of resistance and perspectives for future therapies against hepatitis B infections: Lessons to be learned from HIV. Infection 27 (Suppl 2), S45–S51 (1999). https://doi.org/10.1007/BF02561672

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02561672

Keywords

Search

Navigation